SuperworthBristol-Myers Squibb BMY
- Market cap
- $125.6B
- PE
- 13.5×
- 10y median 19.9×
- Forward PE
- 10.4×
- 10y median 10.2×
- Price to sales
- 2.6×
- EV/EBIT
- 12.4×
- Revenue, 12 months
- $49.2B
- +3% on a year ago
- Net margin
- 18.9%
- Free cash flow yield
- 9.1%
Bristol-Myers Squibb trades at 13.5× trailing earnings, cheaper than 90% of the last ten years. Revenue was $49.2B over the last twelve months, up 3% on a year earlier with a 19% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $11B−2% | $11.5B+1% | $11.9B+5% | $12.2B+9% | $11.9B+8% | $12.3B+8% | $11.2B−6% | $12.3B+1% | $12.2B+3% | $12.5B+1% | $11.5B+3% | $13B+6% | |
| Cost of revenue | $2.5B+7% | $2.7B+6% | $2.9B+14% | $3.3B+14% | $3B+18% | $4.8B+75% | $3B+3% | $3.4B+3% | $3.4B+16% | $4.1B−15% | $3.4B+13% | $3.7B+11% |
| Gross profit | $8.5B−5% | $8.7B−1% | $8.9B+2% | $8.9B+7% | $8.9B+6% | $7.5B−14% | $8.2B−9% | $8.9B−0% | $8.8B−2% | $8.4B+12% | $8.1B−1% | $9.2B+4% |
| R&D | $2.2B−7% | $2.5B−1% | $2.7B+16% | $2.9B+28% | $2.4B+6% | $3.2B+29% | $2.3B−16% | $2.6B−11% | $2.5B+7% | $2.6B−19% | $2.6B+17% | $3B+15% |
| SG&A | $2B+4% | $2.1B−9% | $2.4B+34% | $1.9B−0% | $2B−1% | $2.1B+3% | $1.6B−33% | $1.7B−11% | $1.8B−10% | $2.2B+2% | $1.6B+2% | $1.8B+7% |
| $1.9B−9% | $1.3B−21% | −$11.4B | $1.6B−11% | $1.9B+2% | $480M−63% | $3.3B | $2.3B+45% | $3B+57% | $1.4B+196% | $3.3B−1% | $4B+78% | |
| Interest expense | $280M−6% | $316M+8% | $425M+48% | $521M+85% | $505M+80% | $496M+57% | $494M+16% | $485M−7% | $480M−5% | $432M−13% | $411M−17% | $407M−16% |
| Pre-tax income | $2.1B−3% | $1.7B−10% | −$11.5B | $1.3B−31% | $1.7B−22% | $175M−90% | $3B | $1.8B+38% | $3.1B+86% | $1.5B+740% | $3.2B+9% | $4.1B+131% |
| $203M−66% | −$88M−47% | $392M−22% | −$398M+83% | $461M+127% | $99M | $509M+30% | $460M | $919M+99% | $384M+288% | $561M+10% | $770M+67% | |
| Net income | $1.9B+20% | $1.8B−13% | −$11.9B | $1.7B−19% | $1.2B−37% | $72M−96% | $2.5B | $1.3B−22% | $2.2B+82% | $1.1B+1410% | $2.7B+9% | $3.3B+153% |
| $0.93+24% | $0.87−8% | −$5.89 | $0.83−16% | $0.60−36% | $0.04−95% | $1.20 | $0.64−23% | $1.08+80% | $0.53+1225% | $1.31+9% | $1.62+153% | |
| 2.1B−4% | 2B−4% | 2B−4% | 2B−4% | 2B−2% | 2B+0% | 2B+1% | 2B+0% | 2B+0% | 2B+0% | 2B+0% | 2B+1% |
Gross profit: 73 periods, Q2 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.
Operating income: 73 periods, Q2 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: 4 periods, Q4 FY21 to Q4 FY25: printed in the fourth-quarter results release.
EPS, diluted: 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release. Q4 FY11: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release. 7 periods, Q4 FY10 to Q4 FY18: share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY15 to Q4 FY20: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $12.7B | $12.3B to $12.9B | $1.10 | $0.87 to $1.51 | 16 |
| Q4 FY26 | $12.7B | $12.4B to $12.9B | $1.63 | $1.52 to $1.71 | 14 |
| Q1 FY27 | $11.2B | $10.9B to $11.4B | $1.48 | $1.42 to $1.52 | 8 |
| Q2 FY27 | $12.3B | $11.9B to $12.5B | $1.70 | $1.63 to $1.74 | 6 |
| Q3 FY27 | $12.2B | $11.8B to $12.4B | $1.64 | $1.57 to $1.68 | 6 |
| Q4 FY27 | $12.5B | $12.1B to $12.7B | $1.62 | $1.56 to $1.66 | 12 |
| Q1 FY28 | $9.8B | $9.5B to $10B | $1.21 | $1.16 to $1.24 | 13 |
| Q2 FY28 | $10.3B | $10B to $10.5B | $1.41 | $1.35 to $1.44 | 7 |
Peers
Companies in Drug Manufacturers - General nearest Bristol-Myers Squibb's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BMYBristol-Myers Squibb | $125.6B | 13.5× | 19.9× | 10.4× | 2.6× | +3% | 18.9% |
| PFEPfizer | $171.2B | 39.5× | 15.8× | 10.9× | 2.7× | −0% | 6.8% |
| GILDGilead Sciences | $193.5B | n/m | 18.8× | 17.2× | 6.4× | +6% | −10.6% |
| AMGNAmgen | $237.5B | 27.3× | 21.1× | 18.6× | 6.2× | +9% | 23.0% |
| MRKMerck | $358.4B | 116× | 24.9× | 17.5× | 5.4× | +5% | 4.8% |
| BIIBBiogen | $37B | 44.4× | 16.1× | 19.1× | 3.7× | +0% | 8.3% |
| ABBVAbbVie | $504.8B | 80.7× | 27.9× | 19.0× | 7.8× | +10% | 9.8% |
| JNJJohnson & Johnson | $635.8B | 40.0× | 24.3× | 23.4× | 6.4× | +8% | n/m |
| JAZZJazz Pharmaceuticals | $13.9B | 14.6× | 20.2× | n/m | 3.0× | +13% | 20.4% |
| LLYEli Lilly and | $1.2T | 42.7× | 41.4× | 33.9× | 15.0× | +50% | 33.5% |
| Peer median | $237.5B | 41.4× | 21.1× | 18.8× | 6.2× | +8% | 9.1% |
More on Bristol-Myers Squibb
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #2of 51Healthcare stocks with the lowest forward PE
- #2of 33Healthcare stocks with the highest dividend yields
- #3of 17Large drugmakers cheapest against their own PE history
- #6of 25Large drugmakers with the fastest earnings growth
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .